Research Study Summary
A Study of RDC-1036 (ALKS 37) in Adults With Opioid-induced Constipation
The purpose of this study is to assess the safety and tolerability of RDC-1036 (ALKS 37) in adults with opioid-induced constipation.
- 18 to 70 years of age
- BMI of 19 to 35 kg/m2 at screening
- Receiving prescribed opioid medication for the management of chronic, non-cancer, pain
- Diagnosis of opioid-induced constipation (OIC)
- Willingness to stop all laxatives and other bowel regimens from the first study visit following screening until the end of the study. The use of constipation rescue medication will be allowed during the study.
- Pregnancy and/or currently breastfeeding
- Clinically significant medical condition or illness (other than the condition for which the pain medication is being prescribed)
- Receiving treatment with opioid therapy for cancer-related pain, abdominal pain, scleroderma, and/or for the management of drug addiction
- Any GI or pelvic disorder known to affect bowel transit, produce a GI obstruction, or contribute to bowel dysfunction other than opioid-induced constipation (eg, diverticulitis, other intestinal strictures, bezoars)
- Use of medical devices such as pacemakers, infusion pumps, or insulin pumps
- Use of naloxone, Subutex or Suboxone, Revia, Relistor, or Entereg starting 15 days before the first study visit following screening until the end of the study
- Participation in a clinical trial of a pharmacological agent within 30 days before screening
To Learn more
Date Last Changed:
July 23, 2013
Clinical Trial Snapshot
- Both Male and Female
- 18 to 70 Years
- Overall Status
- Facility Type
DISCLAIMER: CenterWatch does not conduct clinical research.
CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies,
contract research organizations, clinical research sites and other interested parties. This information
is designed to help patients find clinical trials of interest and contact the research centers
conducting the trials.